MX2021006505A - Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados. - Google Patents

Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.

Info

Publication number
MX2021006505A
MX2021006505A MX2021006505A MX2021006505A MX2021006505A MX 2021006505 A MX2021006505 A MX 2021006505A MX 2021006505 A MX2021006505 A MX 2021006505A MX 2021006505 A MX2021006505 A MX 2021006505A MX 2021006505 A MX2021006505 A MX 2021006505A
Authority
MX
Mexico
Prior art keywords
peptide
gip
glucose
modified
dependent insulinotropic
Prior art date
Application number
MX2021006505A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Hovard Sparre-Ulrich
Bjørn Behrens Sivertsen
Ditte Riber
Mette Marie Rosenkilde
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of MX2021006505A publication Critical patent/MX2021006505A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021006505A 2018-12-03 2019-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados. MX2021006505A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18209896 2018-12-03
EP19176739 2019-05-27
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues

Publications (1)

Publication Number Publication Date
MX2021006505A true MX2021006505A (es) 2021-10-01

Family

ID=68731999

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006505A MX2021006505A (es) 2018-12-03 2019-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.

Country Status (12)

Country Link
US (3) US12297250B2 (https=)
EP (2) EP3891173A1 (https=)
JP (1) JP7605747B2 (https=)
KR (2) KR20260011770A (https=)
CN (3) CN121449721A (https=)
AU (2) AU2019391300B2 (https=)
BR (1) BR112021010447A2 (https=)
CA (1) CA3121043A1 (https=)
IL (1) IL283385A (https=)
MX (1) MX2021006505A (https=)
SG (1) SG11202105586YA (https=)
WO (2) WO2020115048A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157387A1 (en) * 2019-12-03 2021-06-10 Mette Marie Rosenkilde Optimized gip peptide analogues
CN116113429A (zh) * 2020-07-06 2023-05-12 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途
WO2022007809A1 (zh) * 2020-07-06 2022-01-13 鸿绪生物医药科技（北京）有限公司 新型多肽制剂及其治疗用途
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
KR20240021212A (ko) * 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
WO2023139106A2 (en) 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
UY40349A (es) * 2022-07-13 2024-01-31 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
CN118255864A (zh) * 2022-12-26 2024-06-28 杭州中美华东制药有限公司 Gip受体激动剂及其用途
CN116120425A (zh) * 2022-12-27 2023-05-16 南京赛诺生物技术有限公司 一种glp-1/gip受体双重激动剂及其应用
GB202302686D0 (en) * 2023-02-24 2023-04-12 Imperial College Innovations Ltd Novel compounds
CN121464151A (zh) * 2023-02-24 2026-02-03 Ip2Ipo创新有限公司 化合物
WO2024209050A1 (en) * 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025176999A2 (en) * 2024-02-23 2025-08-28 Ip2Ipo Innovations Limited Novel compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5745335A (en) 1996-06-27 1998-04-28 Gennum Corporation Multi-layer film capacitor structures and method
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
DE69900026T2 (de) 1998-01-30 2001-05-10 Novo Nordisk As Eine injektionsspritze
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2002526554A (ja) 1998-10-07 2002-08-20 メディカル カレッジ オブ ジョージア リサーチ インスティチュート，インコーポレイテッド 骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
PT1171465E (pt) 1999-03-29 2004-12-31 Uutech Ltd Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
GB0404124D0 (en) 2004-02-25 2004-03-31 Univ Ulster Antagonists of GIP
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
EP1444810B1 (en) 2001-09-21 2006-12-06 Koninklijke Philips Electronics N.V. No specific control module? use less specific one
US20030232761A1 (en) 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20050059605A1 (en) 2003-01-31 2005-03-17 Krishna Peri Chemically modified metabolites of regulatory peptides and methods of producing and using same
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
JP2011530507A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
KR101417873B1 (ko) 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
US8450266B2 (en) 2008-08-07 2013-05-28 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CA2877358A1 (en) * 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US10968266B2 (en) 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2018069442A1 (en) 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
US20190352335A1 (en) * 2016-12-19 2019-11-21 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
WO2018124009A1 (ja) 2016-12-26 2018-07-05 花王株式会社 低体温改善剤
CN110087686A (zh) 2016-12-26 2019-08-02 花王株式会社 认知功能改善剂
CN110139672A (zh) 2016-12-26 2019-08-16 花王株式会社 运动调节功能提高剂
PL3630806T3 (pl) 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu

Also Published As

Publication number Publication date
KR20210102911A (ko) 2021-08-20
AU2025237957A1 (en) 2025-10-16
BR112021010447A2 (pt) 2021-08-24
CN113366014B (zh) 2025-10-21
IL283385A (en) 2021-07-29
US20250376499A1 (en) 2025-12-11
US12187773B2 (en) 2025-01-07
CN121449720A (zh) 2026-02-03
JP2022509568A (ja) 2022-01-20
CN113366014A (zh) 2021-09-07
SG11202105586YA (en) 2021-06-29
EP3891174A1 (en) 2021-10-13
US12297250B2 (en) 2025-05-13
US20220025010A1 (en) 2022-01-27
KR102906485B1 (ko) 2025-12-31
KR20260011770A (ko) 2026-01-23
WO2020115049A1 (en) 2020-06-11
EP3891173A1 (en) 2021-10-13
US20220298218A1 (en) 2022-09-22
CN121449721A (zh) 2026-02-03
CA3121043A1 (en) 2020-06-11
AU2019391300B2 (en) 2025-06-26
WO2020115048A1 (en) 2020-06-11
AU2019391300A1 (en) 2021-07-01
JP7605747B2 (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
MX2021006505A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
PH12018501411B1 (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
IL288479A (en) Glucagon-like peptide 1 receptor agonists
CY1125582T1 (el) Συνθεσεις και μεθοδοι για εκλυση μακρας διαρκειας των ανταγωνιστων της εκλυτικης ορμονης των γοναδοτροπινων (gnrh).
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
DK3756682T3 (da) Genetisk modificerede celler, der omfatter et modificeret gen fra det konstante område af den humane t-cellereceptor alpha
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
CY1123738T1 (el) Προσδετες που ενισχυουν τη βιοδραστικοτητα των γοναδοτροπινων
MX2022006737A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
SI3765024T1 (sl) Nova farmacevtska formulacija, ki vsebuje dvojne antagoniste receptorja NK-1/NK-3
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
MA50047A (fr) Administration orale d'analogues peptidiques de glp-1
EP4361173A3 (en) Long-acting gip peptide analogues
EP3650464A4 (en) PEPTIDE COMPOUND AND ITS APPLICATION AND A COMPOSITION WITH THE PEPTIDE COMPOUND
MX394179B (es) Liraglutida en afecciones cardiovasculares.
EP3873693C0 (en) WIRE DISPENSER
IL285432A (en) Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides
EP4026844A4 (en) HIGH-AFFINITY T-CELL RECEPTOR THAT RECOGNIZES SSX2
MX390677B (es) Composiciones farmaceuticas de liberacion sostenida retardada con anfetamina
MY199261A (en) Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
EP3893919A4 (en) PEGYLATED GROWTH HORMONE ANTAGONISTS
EP3308188A4 (en) MAKING THE IMPLEMENTATION OF AN ACTIVE SCAN
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина